Joo Bio, Park Mi-Suk, Lee Soo Hyeon, Choi Hye Jin, Lim Seung Tack, Rha Sun Young, Rachmilevitch Itay, Lee Young Han, Suh Jin-Suck
Department of Diagnostic Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Pfizer Oncology, Seoul, Korea.
Yonsei Med J. 2015 Mar;56(2):503-9. doi: 10.3349/ymj.2015.56.2.503.
We evaluated the safety and effectiveness of the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate Conformal Bone System for the palliation of painful bone metastases.
Our Institutional Review Board approved this study, and all patients gave informed consent prior to enrollment. A total of six painful metastatic bone lesions in five patients were treated using MRgFUS with the ExAblate Conformal Bone System for pain palliation. The follow-up sessions were at 3 days, 2 weeks, 1, 2, and 3 months, and 1 year after treatment. Efficacy was evaluated by the changes in visual analog scale (VAS) scores. At 3-months and 1-year follow-ups, unenhanced computed tomography and contrast-enhanced MR imaging examinations were performed. All adverse events were assessed to evaluate treatment safety.
All patients showed significant pain relief within 2 weeks. Two patients experienced complete pain reduction that lasted for 1 year. Two other patients showed pain relief measured as VAS scores of 2 and 4 on their last follow-up. Although the remaining patient had experienced significant pain relief in two lesions, the VAS score re-increased on his last follow-up. The size of the enhancing soft tissue mass in metastatic lesions decreased, and new bone formation was seen on follow-up images. Although adverse events were not serious, non-specific leg pain and second degree skin burn were noted.
MRgFUS was demonstrated to be effective palliative treatment within 2 weeks in selected patients with painful bone metastases.
我们评估了使用适形骨消融系统的磁共振引导聚焦超声(MRgFUS)缓解骨转移疼痛的安全性和有效性。
我们的机构审查委员会批准了本研究,所有患者在入组前均签署了知情同意书。共有5例患者的6个疼痛性转移性骨病变接受了使用适形骨消融系统的MRgFUS治疗以缓解疼痛。随访时间为治疗后3天、2周、1个月、2个月、3个月和1年。通过视觉模拟量表(VAS)评分的变化评估疗效。在3个月和1年随访时,进行了平扫计算机断层扫描和对比增强磁共振成像检查。评估所有不良事件以评价治疗安全性。
所有患者在2周内均显示出明显的疼痛缓解。2例患者疼痛完全缓解并持续了1年。另外2例患者在最后一次随访时VAS评分为2分和4分,显示疼痛缓解。尽管其余1例患者的2个病变疼痛明显缓解,但在最后一次随访时VAS评分再次升高。转移性病变中强化软组织肿块的大小减小,随访图像上可见新骨形成。尽管不良事件不严重,但记录到了非特异性腿痛和二度皮肤烧伤。
对于选定的骨转移疼痛患者,MRgFUS在2周内被证明是有效的姑息治疗方法。